Therapy with mesenchymal precursor cells (MPC) reduces heart attacks, non-fatal strokes and cardiac death in patients with high-risk, heart failure with reduced ejection fraction (HFrEF) and high levels of inflammation, reveal data from the DREAM HF Trial.